|Human cell-derived rhG-CSFR extracellular domain (Catalog#10218-HCCH)|
|0.2 μm filtered solution in PBS with 5% trehalose|
|This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human G-CSFR extracellular domain (rhG-CSFR; Catalog #10218-HCCH; aa 1-621; NP_000751.1). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.|
ELISA: 0.5 μg/mL
This antibody can be used at 0.5 μg/mL with the appropriate secondary reagents to detect G-CSFR. The detection limit for G-CSFR is approximately 2.5 ng/well.
ELISA(Det): 0.1-1 µg/ml
This antibody will detect Human G-CSF R / CD114 / CSF3R in ELISA pair set (Catalog: # SEK10218). In a sandwich ELISA, it can be used as detection antibody when paired with (Catalog: # 10218-MM06).
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
Granulocyte Colony Stimulating Factor Receptor (G-CSFR), also known as CD114, which belongs to the cytokine receptor superfamily, is a cell surface receptor for colony stimulating factor 3 (CSF3). It is a critical regulator of granulopoiesis. This type I membrane protein has a composite structure consisting of an immunoglobulin(Ig)-like domain, a cytokine receptor-homologous (CRH) domain and three fibronectin type III (FNIII) domains in the extracellular region. Mutations in the G-CSF receptor leading to carboxy-terminal truncation transduce hyperproliferative growth responses, and are implicated in the pathological progression of severe congenital neutropenia (SCN) to acute myelogenous leukemia (AML). Additionally, autocrine/paracrine stimulation of G-CSFR may be important in the biology of solid tumors, including metastasis.